16 July 2013Americas

Glenmark confirms Vimpat challenge

Pharmaceutical company Glenmark Generics has confirmed that it has filed Abbreviated New Drug Applications (ANDAs) with the US Food and Drug Administration (FDA) to market generic versions of epilepsy drug Vimpat.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk